Answers are grounded in this paper and cite their sources.
In this work, the reaction between the drug gatifloxacin (as a ligand) with Ru(III) ions was investigated and the resulting complex was structurally and morphologically characterized. The structural properties of the complex were assessed using elemental analyses, molar conductance, thermogravimetry, UV-Vis, and IR spectroscopies, where the morphological characteristics were evaluated using SEM-EDX and XRD methods. The analyses suggested that two ligand molecules were coordinated to the Ru(III) ion via the nitrogen atoms of piperazine rings. The complex was formulated as [Ru(L) 2 (Cl) 2 ]Cl, where the Ru(III) ion has a six-coordinate mode, and the coordination sphere is complemented by chlorine atoms. The interaction of the ligand with the Ru(III) ions leads to the product having an organized smooth plate-like structure with a main diameter of 39.42 nm. The RuO 2 oxide in the nanoscale range was generated by the thermal decomposition of the [Ru(L) 2 (Cl) 2 ]Cl complex at 600 o C for 3 hours. SEM micrographs indicated that the RuO 2 material possesses uniform and organized microstructures with many internal cavities enabling it to be used as a catalyst for the heterogeneous degradation of dyes and organic pollutants.
No takes yet. Share an insight, caveat, or question.
Khaled Althubeiti (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: